After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued success for pulsed field ablation as trends to watch this year.

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

RBC Capital Mkts has recently raised Medtronic PLC (MDT) stock to Outperform rating, as announced on October 10, 2024, according to Finviz. Earlier, on August 21, 2024, Oppenheimer had reiterated the ...

First Hawaiian Bank grew its stake in shares of Medtronic plc (NYSE:MDT – Free Report) by 11.5% in the fourth quarter, ...

Bernstein analyst Lee Hambright lowered the firm’s price target on Medtronic (MDT) to $93 from $97 and keeps an Outperform rating on the shares ...

Medtronic is by most measures fairly valued because it has a Very low P/E ratio, a lower P/B ratio than its sector average, ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

(Reuters) -Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the ...

Shocking profiteering in healthcare system continues to harm patients nationwide. • The 2024 Shkreli Awards highlighted the 10 most egregious examples of healthcare profiteering and dysfunction, ...

Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.

From new partnerships to acquisitions, here are four key developments from spine and orthopedic medtech companies since Jan. 1.